Table 1.
Malaria transmission intensity and anti-circumsporozoite antibody titres by site
| Per-protocol cohort (C3C, R3C, R3R) | Incidence (cases per year) | Serology cohort (C3C, R3C, R3R) | CSbase(EU/mL) | CSpeak(EU/mL) | CSboost(EU/mL) | |
|---|---|---|---|---|---|---|
| Age 6–12 weeks | ||||||
| Kilifi | 102, 95, 90 | 0·04 | 104, 97, 87 | 0·39 (0·25–2·71) | 247 (20–1326) | 187 (11–1041) |
| Korogwe | 183, 191, 191 | 0·09 | 74, 64, 64 | 0·34 (0·25–1·59) | 232 (20–905) | 163 (21–559) |
| Bagamoyo | 245, 249, 252 | 0·15 | 70, 78, 74 | 0·34 (0·25–1·46) | 163 (15–844) | 149 (14–609) |
| Lambarene | 62, 75, 72 | 0·17 | 64, 67, 72 | 0·28 (0·25–1·10) | 283 (58–1374) | 207 (15–1240) |
| Manhica | 188, 187, 193 | 0·20 | 100, 107, 113 | 0·27 (0·25–0·70) | 327 (46–1471) | 254 (14–1141) |
| Lilongwe | 257, 250, 247 | 0·42 | 104, 96, 99 | 0·39 (0·25–2·30) | 218 (30–1213) | 104 (7–668) |
| Agogo | 221, 209, 209 | 0·84 | 70, 70, 63 | 0·46 (0·25–3·00) | 151 (7–858) | 128 (3–850) |
| Kombewa | 196, 193, 195 | 1·62 | 68, 76, 75 | 0·38 (0·25–2·51) | 202 (3–1250) | 121 (2–876) |
| Kintampo | 100, 101, 98 | 1·69 | 66, 69, 68 | 0·62 (0·25–3·20) | 148 (24–829) | 91 (0–591) |
| Siaya | 229, 231, 221 | 3·12 | 91, 94, 94 | 0·46 (0·25–2·51) | 208 (4–1442) | 155 (0–1272) |
| Nanoro | 224, 224, 217 | 3·14 | 65, 72, 64 | 0·94 (0·25–7·10) | 115 (3–862) | 156 (19–1101) |
| Age 5–17 months | ||||||
| Kilifi | 172, 172, 163 | 0·08 | 60, 72, 69 | 0·25 (0·25–0·25) | 593 (41–2387) | 231 (20–928) |
| Korogwe | 293, 282, 286 | 0·10 | 66, 69, 66 | 0·25 (0·25–0·25) | 540 (178–2098) | 303 (130–965) |
| Bagamoyo | 236, 242, 228 | 0·27 | 69, 68, 67 | 0·28 (0·25–1·59) | 450 (52–1820) | 297 (42–1417) |
| Lambarene | 196, 196, 187 | 0·23 | 74, 78, 68 | 0·27 (0·25–0·86) | 374 (55–1621) | 193 (21–1121) |
| Manhica | * | * | 81, 76, 76 | 0·26 (0·25–0·30) | 621 (141–2315) | 205 (36–834) |
| Lilongwe | 185, 183, 176 | 0·23 | 70, 73, 77 | 0·26 (0·25–0·72) | 360 (103–1630) | 277 (65–747) |
| Agogo | 191, 183, 188 | 1·01 | 69, 70, 68 | 0·28 (0·25–1·80) | 667 (208–2703) | 267 (89–909) |
| Kombewa | 312, 301, 315 | 1·64 | 86, 65, 75 | 0·30 (0·25–1·41) | 716 (204–2794) | 306 (92–1386) |
| Kintampo | 301, 310, 299 | 1·71 | 75, 71, 74 | 0·31 (0·25–1·91) | 726 (112–2046) | 260 (33–1339) |
| Siaya | 252, 242, 240 | 3·15 | 93, 99, 89 | 0·37 (0·25–4·34) | 677 (52–3154) | 342 (67–1959) |
| Nanoro | 198,195, 194 | 2·69 | 67, 70, 72 | 0·37 (0·25–4·24) | 689 (184–3010) | 499 (161–1922) |
Cases are based on the primary case definition of clinical malaria: illness in a child brought to a study facility with a measured temperature of ≥37·5°C and Plasmodium falciparum asexual parasitaemia at a density of >5000 parasites per μL. Incidence is based on reported cases of malaria in the per-protocol population from 2·5 months to the end of the study. The serology cohort includes some children from the intention-to-treat population not included in the per-protocol population. CS antibody titres are presented as geometric mean titres with 95% ranges (2·5–97·5 percentile). CS=anti-circumsporozoite. R3C=three doses of RTS,S/AS01 and a booster with a comparator vaccine. R3R=three doses of RTS,S/AS01 and a booster with RTS,S/AS01. C3C=three doses of comparator vaccine and a booster with a comparator vaccine.
No data in the per-protocol cohort.